Drugs in Dev.
Rheumatology
Phase III
Belgium 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Details : Certolizumab Pegol is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Spondylarthropathies.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 16, 2010
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
